Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E CSF1R pos |
| Therapy | Pexidartinib + Vemurafenib |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E CSF1R pos | melanoma | sensitive | Pexidartinib + Vemurafenib | Preclinical | Actionable | In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769). | 25939769 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25939769) | Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. | Full reference... |